AC 137 pramlintide analog of amylin: Began a one-year pivotal Phase III trial to test improved glucose control, with another one-year pivotal trial to start by

Amylin Pharmaceuticals Inc. (AMLN), San Diego Product: AC 137 pramlintide analog of amylin Indication: Type II diabetes requiring insulin treatment Status: Began a one-year pivotal Phase III trial to ...